Eric van der Helm
@EricvdHelm
Followers
854
Following
526
Media
241
Statuses
1K
Blogging at https://t.co/fcSWIRe0LZ | Science @SNIPRBiome l Previous at the Novo Nordisk Foundation Center for Biosustainability in @Sommergroup | #synbio
Copenhagen, Denmark
Joined November 2011
Heading to London for the @Jefferies Global Healthcare Conference Nov 17–20. @sniprbiome will be on-site, together w. @groendahl. We’re excited to share insights on our proprietary CRISPR platform and our differentiated #AMR pipeline. #JefferiesHealthcare
0
1
0
I couldn’t be prouder of the SNIPR team today! We’ve just closed a €35 million Series B to push the boundaries of antimicrobial therapy. Huge thanks to our investors, partners, and team members that were part of this journey.
We proudly announced the close of a €35 million Series B financing! Learn more about this milestone in the press release below. #AMR #CRISPR #SeriesB
0
0
1
Very proud to see our lead asset now being dosed in patients for the first time. Big congrats to the whole team!
📢 SNIPR BIOME Announces First Patient Dosed in its Phase 1b Clinical Trial of SNIPR001 in Patients with Hematological Cancer— the first CRISPR-armed phage therapeutic designed to target E. coli in the gut. @CARB_X
0
0
0
Looking forward to meeting at #BIO2025! Reach out if you'd like to connect with @groendahl and @EricvdHelm in Boston June 16-19. DM here or email partnering@sniprbiome.com
0
1
0
@groendahl and @EricvdHelm will be attending next week's #BioEquity in Bruges🇧🇪. Reach out to learn more about our recent progress and updates of our pipeline. #partnering #BioEquityEurope
0
1
0
I’m looking forward to meeting everyone in Berlin next week, so if you’re also attending @SPRIND feel free to send me a message
Meet SNIPR BIOME next week: Jakob & @EricvdHelm at Venture @SPRIND Berlin (Apr 8), Alice discussing untreatable infections at EU Parliament, and @groendahl & Anders at #ESCMIDGLOBAL Vienna (Apr 10-14). Don't miss our SNIPR001 poster (P2537) Apr 13, 12:00–13:30, Hall D!
0
0
0
SNIPR Biome strengthens IP portfolio with a patent granted for a novel #CRISPR-Cas system! Read more in the press release below.
1
1
2
It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS, indeterminate dendritic cell histiocytosis
1K
5K
19K
On February 25-26, @groendahl and I will be in Basel for the #AMRConference. We’re excited to discuss how @sniprbiome CRISPR technology can help combat #AntimicrobialResistance. If you're attending, feel free to reach out via partnering@sniprbiome.com
0
1
6
Attending #JPM2025 this January? @groendahl and @EricvdHelm will be present and involved in JPM week events. Reach out if you want to meet in San Francisco!
0
1
0
Seven days to #BioEurope! Reach out if you are at #BioEurope and want to know more about @sniprbiome progress in AMR and Microbial Gene Therapy.
0
1
0
Want to know more about building large #phage libraries using cell-free synthesis? Check out our new @sniprbiome scientific article in @OUPSynBio. Big congrats to PhD student Camilla Schoopp Kristensen for leading this work.
🧬 New publication alert! Our team has just published a new article on advancing bacteriophage engineering in the @OUPSynBio. Congratulations to authors Camilla Kristensen, Anders Østergaard, Mogens Kilstrup (@DTUbioengineer), @EricvdHelm & Adam Takos. https://t.co/4GGqPheezE
0
0
4
Great to see David Baker’s groundbreaking work recognized with the 2024 Nobel Prize in Chemistry. It was an incredible experience to have worked in his lab at the @UWproteindesign over a decade ago and to see the work he's been honored for today!
BREAKING NEWS The Royal Swedish Academy of Sciences has decided to award the 2024 #NobelPrize in Chemistry with one half to David Baker “for computational protein design” and the other half jointly to Demis Hassabis and John M. Jumper “for protein structure prediction.”
0
0
1
We are pleased to share that SNIPR Biome has received funding from the @gatesfoundation to advance our microbial gene therapy platform aimed at improving Environmental Enteric Dysfunction in pregnant women from low- and middle-income countries (LMICs).
0
1
8
One of the many perks as an Unveil Bio customer: Edible plasmids! Get your plasmids sequenced at https://t.co/mCWLXOvChX
0
1
2
Exciting news: SNIPR Biome receives funding from @CARB_X to support advancement of CRISPR-medicine SNIPR001 into Phase 1b/2a clinical trials in haematological cancer patients! 👇 https://t.co/rfVsArifR9
0
4
7
A study in @NatureComms explores the distribution, evolution and functions of the K1 capsule at a population level and its important role in the pathogenesis of E. coli. https://t.co/BVjs06FQdn
1
10
25
A recent study by SNIPR Biome confirmed the feasibility of using CRISPR-armed phages to selectively target clinically-relevant E. coli. The findings highlight new possibilities in using phage therapy to treat antibiotic-resistant bacteria. Read more: https://t.co/QVhT8zgLNT
1
2
10
A great example from the Baker lab on how de novo protein design can be very powerful if you have the right problem. In this case, achieving very high selectivity for a receptor subtype and trapping it in a very specific conformation. https://t.co/RwdEddiDxq Short 🧵
1
45
259
🎉In an incredible milestone for our team and science as a whole, I'm proud to announce the promising results of our pioneering CRISPR-based microbial gene phage therapy, SNIPR001.
📣 Today we report positive clinical interim results for our groundbreaking, first-in-human, CRISPR-based microbial gene therapy. Read the release here 👇 https://t.co/acJjIzAoAr
#SNIPR #SNIPR001 #oncology #infection
0
2
21